Bentham is offering subject-based scholarly content collections which are tailored to meet specific research needs. Researchers can access related articles from current and back volumes by purchasing access to these collections. Subscribers will also have access to new articles as soon as they are published and added to these collections. With new articles being added to these collections on a daily basis, the collections serve as an ideal tool to keep researchers updated with new developments in the respective fields.
Journal: Current Signal Transduction Therapy Volume: 5 Issue: 3 Year: 2010 Page: 212-222 Author(s): Kenshiro Shiraishi, Keiichi Nakagawa, Yuzuru Niibe, Yoshiro Ishiwata, Shoji Yokochi, Kuni Ohtomo, Kouji Matsushima
Journal: Current Molecular Pharmacology Volume: 4 Issue: 2 Year: 2011 Page: 79-95 Author(s): Nobuyuki Hamada, Munetoshi Maeda, Kensuke Otsuka, Masanori Tomita
Journal: Current Nanoscience Volume: 12 Issue: 3 Year: 2016 Page: 372-377 Author(s): M. P. Calatayud, L. Asin, A. Tres, G. F. Goya, M. R. Ibarra
Journal: Current Chemical Biology Volume: 5 Issue: 3 Year: 2011 Page: 168-176 Author(s): Pompilio Elio Torremante, Harald Rosner
Journal: Endocrine, Metabolic & Immune Disorders - Drug Targets Volume: 10 Issue: 1 Year: 2010 Page: 1-7 Author(s): Moustapha Zoubir, Thomas Tursz, Cedric Menard, Laurence Zitvogel, Nathalie Chaput
Journal: Infectious Disorders - Drug Targets Volume: 21 Issue: 6 Year: 2021 Page: 1-7 Author(s): Maryam Pourhajibagher,Abbas Bahador
Journal: Current Pharmaceutical Design Volume: 21 Issue: 3 Year: 2015 Page: 5453-5466 Author(s): Eirik Johansson Solum, Oyvind W. Akselsen, Anders Vik, Trond Vidar Hansen
Journal: Current Molecular Pharmacology Volume: 4 Issue: 2 Year: 2011 Page: 135-140 Author(s): William F. Morgan
Journal: Current Molecular Medicine Volume: 10 Issue: 3 Year: 2010 Page: 335-349 Author(s): G. Pradel, M. Schlitzer
Journal: Current Drug Targets - Immune, Endocrine & Metabolic Disorders Volume: 5 Issue: 1 Year: 2005 Page: 73-77 Author(s): Yoh Matsumoto
Previous Next